Comparison 5. All children: echinocandin versus lipid preparation of amphotericin B.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mortality (all cause)	2	187	Risk Ratio (M‐H, Random, 95% CI)	1.78 [0.76, 4.17]
2 Mortality (related to fungal infection)	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
3 Complete resolution of fungal infection	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4 Partial resolution of fungal infection	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
5 Resolution of fever in suspected fungal infection	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
6 Progression of disease requiring change / addition of an antifungal agent	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
7 Breakthrough fungal infection requiring change / addition of an antifungal agent	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
8 Any clinically significant adverse reactions attributed to the antifungal agent resulting in discontinuation, dose reduction or change in therapy	2	188	Risk Ratio (M‐H, Random, 95% CI)	0.32 [0.08, 1.27]
9 Any clinically significant adverse reactions attributed to the antifungal agent (total)	2	188	Risk Ratio (M‐H, Random, 95% CI)	0.94 [0.67, 1.33]
10 Nephrotoxicity	1	84	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
11 Hypokalaemia	1	106	Risk Ratio (M‐H, Random, 95% CI)	0.47 [0.18, 1.27]
12 Hepatotoxicity (>2.5 X ULN)	1	55	Risk Ratio (M‐H, Random, 95% CI)	1.67 [0.16, 17.32]
13 Infusion‐related reactions	1	106	Risk Ratio (M‐H, Random, 95% CI)	0.73 [0.30, 1.77]
14 Gastrointesintal toxicity	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
15 Neurological disturbances	1	106	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
16 Haematological disturbances	1	106	Risk Ratio (M‐H, Random, 95% CI)	1.56 [0.60, 4.07]
17 Length of stay	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
18 Quality of life	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
19 Cost	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]